中国药师
中國藥師
중국약사
CHINA PHARMACIST
2014年
9期
1526-1528
,共3页
反流性食管炎%埃索美拉唑%质子泵抑制药%复发%维持治疗
反流性食管炎%埃索美拉唑%質子泵抑製藥%複髮%維持治療
반류성식관염%애색미랍서%질자빙억제약%복발%유지치료
Reflux esophagitis%Esomeprazole%Proton pump inhibitor%Recurrence%Maintenance treatment
目的：探究不同剂量埃索美拉唑维持治疗及预防反流性食管炎( RE)复发的效果。方法：240例RE患者按病情严重程度分为轻度组和重度组各120例，两组患者再分别随机分为四组，即全剂量持续治疗组、半剂量持续治疗组、间歇治疗组及按需治疗组，随访6个月后分别比较各组患者不同剂量埃索美拉唑维持治疗下的GERD-HRQI评分、RE复发率及不良反应发生率。结果：不同剂量治疗组6个月后GERD-HRQI评分、RE复发率和不良反应发生率组间比较差异有统计学意义( P<0.05)。轻度和重度组中，按需治疗组的GERD-HRQI评分和RE复发率均显著高于其他3个剂量组(P<0.05)，全剂量持续治疗组的药品不良反应发生率显著高于其他3个剂量组(P<0.05)。结论：埃索美拉唑小剂量间歇治疗可有效预防RE复发，并降低不良反应发生率和治疗成本，值得推广。
目的：探究不同劑量埃索美拉唑維持治療及預防反流性食管炎( RE)複髮的效果。方法：240例RE患者按病情嚴重程度分為輕度組和重度組各120例，兩組患者再分彆隨機分為四組，即全劑量持續治療組、半劑量持續治療組、間歇治療組及按需治療組，隨訪6箇月後分彆比較各組患者不同劑量埃索美拉唑維持治療下的GERD-HRQI評分、RE複髮率及不良反應髮生率。結果：不同劑量治療組6箇月後GERD-HRQI評分、RE複髮率和不良反應髮生率組間比較差異有統計學意義( P<0.05)。輕度和重度組中，按需治療組的GERD-HRQI評分和RE複髮率均顯著高于其他3箇劑量組(P<0.05)，全劑量持續治療組的藥品不良反應髮生率顯著高于其他3箇劑量組(P<0.05)。結論：埃索美拉唑小劑量間歇治療可有效預防RE複髮，併降低不良反應髮生率和治療成本，值得推廣。
목적：탐구불동제량애색미랍서유지치료급예방반류성식관염( RE)복발적효과。방법：240례RE환자안병정엄중정도분위경도조화중도조각120례，량조환자재분별수궤분위사조，즉전제량지속치료조、반제량지속치료조、간헐치료조급안수치료조，수방6개월후분별비교각조환자불동제량애색미랍서유지치료하적GERD-HRQI평분、RE복발솔급불량반응발생솔。결과：불동제량치료조6개월후GERD-HRQI평분、RE복발솔화불량반응발생솔조간비교차이유통계학의의( P<0.05)。경도화중도조중，안수치료조적GERD-HRQI평분화RE복발솔균현저고우기타3개제량조(P<0.05)，전제량지속치료조적약품불량반응발생솔현저고우기타3개제량조(P<0.05)。결론：애색미랍서소제량간헐치료가유효예방RE복발，병강저불량반응발생솔화치료성본，치득추엄。
Objective:To explore the effectiveness and recurrence prevention of esomeprazole at different doses in the patients with reflux esophagitis ( RE) . Methods:Totally 240 patients with RE were divided into mild or severe group with 120 cases in each accord-ing to the illness severity. The two groups were respectively divided into four groups according to the random number table, namely the full dose treatment group, half dose treatment group, intermittent treatment group and on-demand treatment group. The groups were fol-lowed up for 6 months, and GERD-HRQI scores, the recurrence rate and incidence of adverse reactions in all the groups were com-pared. Results:After the 6-month follow-up, the differences in the GERD-HRQI scores, recurrence rate and incidence of adverse re-actions among the groups with different doses were statistically significant (P<0. 05). The GERD-HRQI scores and RE recurrence rate in on-demand treatment group were significantly higher than those in the other groups(P<0. 05), and the incidence of adverse re-actions in the total dose treatment group was significantly higher than that in the other groups (P<0. 05). Conclusion: Intermittent treatment with esomeprazole at small dose can effectively prevent RE recurrence, reduce the incidence of adverse reactions and treat-ment costs, which is worthy of promotion.
